Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18–49: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study.

MLA

Wang, Yanxia, et al. “Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18–49: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study.” Vaccines, vol. 12, no. 8, Aug. 2024, p. 827. EBSCOhost, https://doi.org/10.3390/vaccines12080827.

APA

Wang, Y., Shi, G., Wang, X., Xie, Z., Gou, J., Huang, L., Huang, H., You, W., Wang, R., Yang, Y., Wang, F., Zhu, T., & Zhao, D. (2024). Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18–49: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study. Vaccines, 12(8), 827. https://doi.org/10.3390/vaccines12080827

Chicago

Wang, Yanxia, Gang Shi, Xue Wang, Zhiqiang Xie, Jinbo Gou, Lili Huang, Haitao Huang, et al. 2024. “Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18–49: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study.” Vaccines 12 (8): 827. doi:10.3390/vaccines12080827.